About: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 September 1996

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у вересні 1996 (uk) article scientifique publié en 1996 (fr) im September 1996 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en setiembre de 1996 (ast) scientific article published on 01 September 1996 (en)
publication date	wds:Q71953129-D8027ED0-ACFD-4F52-AC5D-6433C2FC84F8
publication date	1996-09-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q71953129-24DADBBC-E821-4490-991E-1ADF490ED288 wds:Q71953129-3921EDA7-C2DB-4517-8F51-463A250EC818 wds:Q71953129-5C33E507-7D5B-42B3-96F4-A2C27C41029D wds:Q71953129-B16B0896-A937-4349-BAC6-1F4053E59CDB wds:Q71953129-C467C95A-B038-4F9C-BE08-D1259A5153FF wds:Q71953129-C60088ED-A5DD-4FC9-BD2C-842EBBB51499 wds:Q71953129-C92E0544-603E-4E7D-A787-21CD2A33C749 wds:Q71953129-D27C00E4-93EB-4F63-8890-9E69974BB706
author name string	P Angeli R Fogari F Bodin R Heath C Hereng C Porcellati N J Holwerda P Oddou-Stock
rdfs:label	Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril (en) Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril (nl)
skos:prefLabel	Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril (en) Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril (nl)
name	Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril (en) Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril (nl)
title	wds:Q71953129-2C943266-62DD-43F5-A230-C2A6EBD8276E
title	Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril (en)
page(s)	wds:Q71953129-06785869-7004-4960-BDD7-78197264A6BD
page(s)	1147-1151
instance of	wds:Q71953129-AEC2DDBF-7567-4952-BE98-E0B823D2D945
instance of	scholarly article
main subject	wds:Q71953129-3AC8D4CE-C37C-4ABF-BF14-5B35B4169B31 wds:Q71953129-71EBCDB4-C4D3-42E2-8C68-F91DAFA50103 wds:Q71953129-7AE56A01-CC3B-4FCA-BD2D-87331EE56638
main subject	enalapril placebo essential hypertension
PubMed ID	wds:Q71953129-A01F2FF0-7025-4511-BC30-BCDDA8FDCB2A
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8986917
PubMed ID	8986917
published in	wds:Q71953129-0235A525-B3EC-4F5F-88D9-16E1D71BC8F4
published in	Journal of Hypertension
issue	wds:Q71953129-C1F7DC77-A0D2-48C2-83E5-C1855DAEAF31
volume	wds:Q71953129-C04FB1A3-8F1B-4E2A-8A8E-97F4762464B5
issue	9
volume	14
DOI	wds:Q71953129-D6C79D54-D95F-4B45-ADB1-D5778FA12F0B
DOI	http://dx.doi.org/10.1097/00004872-199609000-00016
DOI	10.1097/00004872-199609000-00016
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q71953129
is cites work of	Efficacy of angiotensin II receptor antagonists in preventing headache: a systematic overview and meta-analysis Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension Valsartan. A review of its pharmacology and therapeutic use in essential hypertension Valsartan in heart failure patients previously untreated with an ACE inhibitor Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril Efficacy and safety of valsartan compared with enalapril at different altitudes. Absence of effect of chronic angiotensin II type 1 receptor blockade on endogenous kinin concentrations-induced paw edema model in the rat Efficacy of valsartan in patients aged > or =65 years with systolic hypertension Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators Efficacy and tolerability of valsartan in combination with hydrochlorothiazide in essential hypertension The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension Population Pharmacokinetic-Pharmacodynamic Modelling of Angiotensin Receptor Blockade in Healthy Volunteers Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan How do angiotensin II receptor antagonists affect blood pressure? Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly Optimizing hypertension management in clinical practice Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker A comparison of intervention with losartan or captopril in acute myocardial infarction A systematic review and network meta-analysis of the comparative efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension Effect of valsartan on renal function in patients with hypertension and stable renal insufficiency Expression, secretion, and inhibition of angiotensin-converting enzyme in cultured human bronchial epithelial cells A randomized, double blind, placebo-controlled, multicenter phase II trial of Allisartan Isoproxil in essential hypertensive population at low-medium risk Formulation and bioequivalence of two valsartan tablets after a single oral administration. Valsartan. Just a second-line antihypertensive drug
is cites work of	wds:Q35014556-0C0D1815-D78E-4AFC-8304-CFB212DA710A wds:Q44534080-4B3AC2D1-D79A-48E8-8801-569B894BE6A9 wds:Q77309728-E4051B72-3E0E-42E7-85F7-828ED8AFF6EB wds:Q78125300-03DDA24A-B37A-4EA5-B738-8D69030A2242 wds:Q34659473-0D7E1E2D-080F-49A8-8BE3-FCA65BA5DD51 wds:Q24240959-00B9D1D8-5A0A-4BD1-A573-9E5A4D1D2519 wds:Q33705777-27A2E8B0-340C-442F-A2E3-74F98D99D4F9 wds:Q36568468-9768AB23-648F-476C-856B-FC32C4A730CB wds:Q34831840-74804A54-6AA4-4F9E-87C8-27CCCC776160 wds:Q73609011-C3E81702-A78D-4045-9AFF-5B48E904DB3F wds:Q24240794-D7CCCF9F-AC3B-49A4-B63E-753669180625 wds:Q34028633-F394AF45-59C6-4F42-A2DF-980D229E3A64

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 195 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software